SenzaGen (SENZA) Q1 2026 earnings summary

Executive summary

• Achieved 10% year-over-year sales growth in Q1 2026, with revenue reaching SEK 15.0 million despite negative foreign exchange effects and subsidiary transition impacts.

• GARD® business drove growth, up 16% year-over-year, with strong performance in the US and chemicals industry.

• Cost base maintained, gross margin at 69%, in line with historical levels.

• Secured a SEK 17.5 million directed share issue, strengthening financial position.

• Gained 14 new customers, including a top five global fragrance and cosmetics group.

Financial highlights

• Revenue: SEK 15.0 million, up 10% year-over-year (14% at constant exchange rates).

• GARD® revenue: SEK 11.0 million, up 16% year-over-year (21% at constant exchange rates).

• Gross profit: SEK 10.3 million; gross margin: 69% (down from 75% last year).

• EBITDA: SEK -1.7 million; EBIT: SEK -2.1 million, impacted by SEK 0.3 million negative FX effects.

• Earnings per share: SEK -0.06 (improved from SEK -0.09 last year).

• Cash and cash equivalents: SEK 38.1 million at quarter-end.

Outlook and guidance

• Continued focus on expanding direct sales to large multinationals and scaling operations through innovation.

• Cost-saving measures at VitroScreen expected to impact results from Q2 2026.

• Market shift toward non-animal testing methods seen as structural and long-term.